Literature DB >> 17403183

Sphingolipid signalling and liver diseases.

Montserrat Marí1, José C Fernández-Checa.   

Abstract

Sphingolipids (SLs) comprise a class of lipids with important structural functions and increasing relevance in cellular signalling. In particular, ceramide has attracted considerable attention owing to its role as a second messenger modulating several cell functions such as proliferation, gene expression, differentiation, cell cycle arrest and cell death. Increasing evidence documents the role of SLs in stress and death ligand-induced hepatocellular death, which contributes to the progression of several liver diseases including steatohepatitis, ischaemia-reperfusion liver injury or hepatocarcinogenesis. Furthermore, recent data indicate that the accumulation of SLs in specific cell subcompartments, characteristic of many sphingolipidoses, contributes to the hepatic dysfunctions that accompany these inherited diseases. Hence, the regulation of the cell biology and metabolism of SLs may open up a novel therapeutic avenue in the treatment of liver diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403183     DOI: 10.1111/j.1478-3231.2007.01475.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  37 in total

1.  Role of ceramides in nonalcoholic fatty liver disease.

Authors:  Mangesh Pagadala; Takhar Kasumov; Arthur J McCullough; Nizar N Zein; John P Kirwan
Journal:  Trends Endocrinol Metab       Date:  2012-05-17       Impact factor: 12.015

Review 2.  Glycosphingolipids and cell death: one aim, many ways.

Authors:  Carmen Garcia-Ruiz; Albert Morales; José C Fernández-Checa
Journal:  Apoptosis       Date:  2015-05       Impact factor: 4.677

3.  Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression.

Authors:  J Barr; J Caballería; I Martínez-Arranz; A Domínguez-Díez; C Alonso; J Muntané; M Pérez-Cormenzana; C García-Monzón; R Mayo; A Martín-Duce; M Romero-Gómez; O Lo Iacono; J Tordjman; R J Andrade; M Pérez-Carreras; Y Le Marchand-Brustel; A Tran; C Fernández-Escalante; E Arévalo; M García-Unzueta; K Clement; J Crespo; P Gual; M Gómez-Fleitas; M L Martínez-Chantar; A Castro; S C Lu; M Vázquez-Chantada; J M Mato
Journal:  J Proteome Res       Date:  2012-03-15       Impact factor: 4.466

4.  FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice.

Authors:  Timothy D Rohrbach; Amon Asgharpour; Melissa A Maczis; David Montefusco; L Ashley Cowart; Pierre Bedossa; Arun J Sanyal; Sarah Spiegel
Journal:  J Lipid Res       Date:  2019-05-20       Impact factor: 5.922

5.  Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection.

Authors:  J-F Li; F Qu; S-J Zheng; H-L Wu; M Liu; S Liu; Y Ren; F Ren; Y Chen; Z-P Duan; J-L Zhang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-09       Impact factor: 3.267

Review 6.  Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease.

Authors:  Harmeet Malhi; Gregory J Gores
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

7.  TNF-{alpha} plays a role in hepatocyte apoptosis in Niemann-Pick type C liver disease.

Authors:  Victoria M Rimkunas; Mark J Graham; Rosanne M Crooke; Laura Liscum
Journal:  J Lipid Res       Date:  2008-09-24       Impact factor: 5.922

8.  Ezetimibe inhibits expression of acid sphingomyelinase in liver and intestine.

Authors:  Yajun Cheng; Fuli Liu; Jun Wu; Yao Zhang; Ake Nilsson; Rui-Dong Duan
Journal:  Lipids       Date:  2009-09-24       Impact factor: 1.880

9.  Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis.

Authors:  Lascelles E Lyn-Cook; Margot Lawton; Ming Tong; Elizabeth Silbermann; Lisa Longato; Ping Jiao; Princess Mark; Jack R Wands; Haiyan Xu; Suzanne M de la Monte
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis.

Authors:  Emmanuel Mas; Marie Danjoux; Virginie Garcia; Stéphane Carpentier; Bruno Ségui; Thierry Levade
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.